Highest-materiality recent filing
Oncology Institute patient data accessed in Vendor cybersecurity incident; operations sustained
On May 20, 2026, Kroll notified TOI that its Vendor detected unauthorized access to TOI patient data systems.
TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M
Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.
Oncology Institute furnishes investor presentation; no material financial updates disclosed
Presentation provided for investor meetings; no earnings or guidance changes.
Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M
Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).
The Oncology Institute appoints Kim Tzoumakas to Board of Directors
Appointed Kim Tzoumakas, CEO of VytlOne National Pharmacy Services, to board effective Feb. 23, 2026.
2026 revenue guidance $630M-$650M, ~28% growth from 2025 midpoint.
TOI appoints Mark Stolper to Board as Audit Committee Chairman
Mark D. Stolper appointed to Board effective Jan 2, 2026; fills a vacancy.
Board member Gabe Ling resigns from The Oncology Institute board effective Dec 1, 2025
Gabriel Ling resigned from the Board of Directors, effective December 1, 2025, with no disagreement with the company.
Oncology Institute provides investor presentation with no specific new financial disclosures
Investor presentation furnished under Regulation FD on November 14, 2025.
TOI Q3 revenue $136.6M (+37% YoY); adjusted loss narrows, raises FY 2025 guidance
Consolidated revenue $136.6M (+36.7% YoY); gross profit $18.9M (+31.7%); net loss $(16.5)M vs $(16.1)M.
Oncology Institute discloses cyber incident impacting fee-for-service collections
Cybersecurity incident at IT software provider may cause brief immaterial delay in fee-for-service collections.
Richard Barasch retires as Chairman of The Oncology Institute; Anne McGeorge appointed as new Chair
Richard Barasch retired as Chairman effective Aug 12, 2025; no disagreement with company.
TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance
Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.
Oncology Institute explores potential PIPE financing as disclosed in investor presentation
The company is considering a private placement (PIPE) of securities according to the investor presentation cover.
TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance
Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.
TOI shareholders approve reverse stock split up to 1:40; re-elect all 8 directors
Reverse stock split approved at ratio between 1:5 and 1:40, board discretion within one year.
The Oncology Institute COO Jeremy Castle resigns effective May 30, 2025
Jeremy Castle provided notice of resignation as COO, effective May 30, 2025.
Oncology Institute regains Nasdaq minimum bid price compliance
Received Nasdaq notice on Apr 9, 2025 that closing bid was $1.00+ for 12 consecutive days through Apr 8.
The Oncology Institute closes ~$16.4M private placement and $4.1M note exchange
Private placement of 12.0M shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.
The Oncology Institute raises $16.5M via private placement and exchanges $4.1M notes
Gross proceeds of ~$16.5M from issuing 12.0M common shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.
TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M
Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.
The Oncology Institute exploring PIPE financing; investor presentation filed March 24
Filing on March 24, 2025 discloses investor presentation dated February 2025 for a potential PIPE financing.
TOI amends Deerfield credit agreement, removes $40M cash covenant, pays down $20M notes
Deerfield waived restrictions on equity issuance and removed the $40M minimum cash covenant.
On May 2, 2025, Jeremy Castle provided notice of his resignation as Chief Operating Officer of The Oncology Institute, Inc. (the “Company”), effective as of May 30, 2025.
Max materiality 0.75 · Median 0.60 · Most common event other_material